Coronavirus: India vaccine giant eyes licence within weeks for Covishield, despite efficacy questions

The world’s largest vaccine manufacturer by volume is set to apply for an emergency licence for a coronavirus vaccine within two weeks, after saying that confusion over the efficacy would not delay its distribution.Serum Institute of India CEO Adar Poonawala also confirmed on Saturday that the Pune-based giant would be able to produce at least 100 million doses a month from early 2021 of Covishield, which was developed by AstraZeneca and Oxford University.Poonawalla spoke after a visit to the…

Read the original article at South China Morning Post